On Monday, June 16, 2014, Dr. Douglas Levine of Memorial Sloan Kettering Cancer Center presented a free webinar focusing on research news that was presented at 2014’s medical meetings. In his hour-long presentation, he focused primarily on new ovarian cancer research that was presented at the American Society of Clinical Oncology’s annual meeting, which took … Continued
Promising new combination treatments for ovarian cancer Dr. Joyce Liu, MD, on behalf of researchers from the National Cancer Institute (NCI) and Dana Farber Cancer Institute (DFCI), presented striking results from a Phase II trial testing the combination of the PARP inhibitor olaparib and the anti-angiogenesis drug cediranib (which blocks tumors from creating new blood … Continued
Kelly Ripa Stars in Public Service Announcements for “QVC Presents Super Saturday LIVE,” Benefitting Ovarian Cancer Research Fund WEST CHESTER, Pa. (June 10, 2014) – Kelly Ripa is shopping to save lives as she fills up her bag with designer deals that will contribute to the cure for ovarian cancer. Ripa, one of the most … Continued
Posted by adavis on January 24, 2014 FOR IMMEDIATE RELEASE: January 24, 2014 Washington, DC—In response to a recent speech by Mike Huckabee, in which he stated that women use oral contraceptives because they “cannot control their libidos or their reproductive systems,” the Ovarian Cancer National Alliance issued the following statement from CEO Calaneet Balas: “In his quest … Continued
Posted by Laura Koontz on June 5, 2014 The 50th Annual Conference of the American Society of Clinical Oncology, held May 30 – June 3 in Chicago, featured a number of promising and thought provoking studies on ovarian cancer. Below is a brief summary of the most notable studies from the meeting. In the coming weeks, we’ll also post … Continued
(June 4, 2014) In a study presented at the American Society of Clinical Oncology annual meeting last week, researchers found that the combination of olaparib and cediranib (Recentin) kept recurrent ovarian cancer from worsening for almost nine months longer than treatment with olaparib alone. For this study, 90 women with recurrent ovarian cancer that was … Continued
Partnership is a word you’ll hear often from the board members of Caring Together, a Partner Member of the Alliance in eastern New York. The support group was organized in 1996 by a survivor and nurse practitioner named Debbie Cullinan. “As the support group continued to grow, women and their families had a strong desire … Continued
The Food and Drug Administration is seeking comments by June 11, 2014 on its review for Olaparib approval. Olaparib is an oral poly ADP-ribose polymerase (PARP) inhibitor that exploits DNA repair pathway deficiencies to preferentially kill cancer cells. AstraZeneca, the company that manufactures the drug, has submitted an application to the FDA for approval of … Continued
(May 16, 2014) Breastfeeding, tubal ligation – also known as having one’s “tubes tied” – and oral contraceptives may lower the risk of ovarian cancer for some women with BRCA gene mutations, according to a comprehensive analysis from a team at the University of Pennsylvania’s Basser Research Center for BRCA. The Basser Research Center for … Continued
Despite recommendations from the federal government that women at high-risk of developing breast and ovarian cancer be offered genetic counseling and testing at no out of pocket cost, a new study finds that few women are offered these services. Researchers at the Virginia Commonwealth University Massey Cancer Center found that over the course of two … Continued
(May 6, 2014) Tumors use numerous mechanisms to escape detection and killing by the immune system. Results from OCRF-funded research, reported May 4, 2014 in the prestigious journal Nature Medicine, show that ovarian cancer cells (and others) establish a protective barrier that prevents anti-tumor immune responses by using tumor-associated blood vessels to kill immune cells. … Continued
This week, the Ovarian Cancer National Alliance submitted comments to the Food and Drug Administration (FDA) about a proposed Guidance for Industry that could have the effect of limiting patient access to “off label” oncology drugs. In cancer, many people are prescribed treatments approved for other uses, but not currently approved for a particular disease. … Continued
Get email updates about research news, action alerts, and ways to join the fight.
